Ipca Laboratories Ltd Share Price (IPCALAB)

Ipca Laboratories Increases Stake in Lyka Labs - 17 Apr, 2024

Ipca Laboratories has increased its stake in Lyka Labs to 40.98% by acquiring 26 lakh equity shares at Rs 139.50 per share, including a premium of Rs 129.50 per equity share on conversion of warrants allotted on preferential basis.

Ipca Laboratories Ltd Shows Bullish Technical Setup - 10 Apr, 2024

Technical analysis suggests a bullish setup for Ipca Laboratories Ltd, with the stock rebounding from its support zone and showing strong trading volumes. The RSI is holding steady at 70 levels, and the breakout of the Cup and Handle pattern confirms a long position with a target price of Rs 1,420 and stop-loss at Rs 1,270.

IPCA Laboratories Sees Long Build-Up and Increased Volume - 05 Apr, 2024

IPCA Laboratories has seen a long build-up with high open interest concentration at 1,280 call strike followed by 1,300 and 1,350 levels. The stock also recorded increased volumes of 51,898 shares, indicating positive investor sentiment. An analyst recommends buying the stock with a target of Rs. 1,530 and stop-loss at Rs. 1,173.

Ipca Laboratories' Shareholders Reject Stock Option Grant - 29 Mar, 2024

Shareholders of Ipca Laboratories have rejected a special resolution to grant stock options to eligible employees, key managerial personnel (KMP) and its whole-time directors. The Employee Stock Option Scheme required at least 75% votes in favour but only received 63.8%.

Ipca Labs Gains After Technology Transfer Agreement With Omexa Formulary - 27 Mar, 2024

Ipca Laboratories Ltd gains for a fifth straight session and announces a technology transfer agreement with Omexa Formulary Pvt Ltd to develop an anti-cancer biosimilar for the global market. Additionally, Zerodol from Ipca expands its reach in various medical segments.

Ipca Laboratories Ltd Up 2.1% on NSE - 22 Mar, 2024

Ipca Laboratories Ltd is up for a third straight session, trading at Rs 1198.8, up 2.1% on the day as of 12:49 IST on the NSE. The stock has slipped around 1.55% in the last month and has a PE ratio of 54.06 based on TTM earnings ending December 23.